α,β-Cyclic-β-benzamido hydroxamic acids: Novel oxaspiro[4.4]nonane templates for the discovery of potent, selective, orally bioavailable inhibitors of tumor necrosis factor-α converting enzyme (TACE)

Bioorganic and Medicinal Chemistry Letters

Volumn 18, Issue 4, 2008, Pages 1288-1292

  Ott, Gregory R ^a   Asakawa, Naoyuki ^a   Liu, Rui Qin ^a   Covington, Maryanne B ^a   Qian, Mingxin ^a   Vaddi, Krishna ^a   Newton, Robert C ^a   Trzaskos, James M ^a   Christ, David D ^a   Galya, Laurine ^a   Scholz, Thomas ^a   Marshall, Will ^a   Duan, James J W ^a  

^a BRISTOL MYERS SQUIBB   (United States)

Author keywords

Amino acid; Matrix metalloprotease; MMP; TACE; TNF converting enzyme

Indexed keywords

HYDROXAMIC ACID DERIVATIVE; LIPOPOLYSACCHARIDE; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA CONVERTING ENZYME INHIBITOR;

ANIMAL EXPERIMENT; ARTICLE; CELL ASSAY; CONTROLLED STUDY; DIASTEREOISOMER; DRUG BIOAVAILABILITY; DRUG PENETRATION; DRUG STRUCTURE; DRUG SYNTHESIS; ENANTIOMER; NONHUMAN; RAT;

ADAM PROTEINS; ADMINISTRATION, ORAL; ALKANES; ANIMALS; BIOLOGICAL AVAILABILITY; CACO-2 CELLS; HUMANS; HYDROXAMIC ACIDS; MATRIX METALLOPROTEINASES; MODELS, MOLECULAR; PROTEASE INHIBITORS; RATS; RATS, SPRAGUE-DAWLEY; SPIRO COMPOUNDS;

EID: 38949095681     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2008.01.030     Document Type: Article

References (20)

1. Newton R.C., and Decicco C.P. J. Med. Chem. 42 (1999) 2295
2. Moreland L.W., Baumgartner S.W., Schiff M.H., Tindall E.A., Fleischmann R.M., Weaver A.L., Ettlinger R.E., Cohen S., Koopman W.J., Mohler K., Widmer M.B., and Blosch C.M. N. Engl. J. Med. 337 (1997) 141
3. Lipsky P.E., van der Heijde D.M.F.M.E., St. Clair W., Furst D.E., Breedveld F.C., Kalden J.R., Smolen J.S., Weisman M., Emery P., Feldmann M., Harriman G.R., and Maini R.N. N. Engl. J. Med. 343 (2000) 1594
4. Machold K.P., and Smolen J.S. Exp. Opin. Bio. Ther. 3 (2003) 351
5. For a recent review, see:. Skotnicki J.S., and Levin J.I. Ann. Rep. Med. Chem. 38 (2003) 153
6. Duan J.J.-W., Chen L., Lu Z., Xue C.-B., Liu R.-Q., Covington M.B., Qian M., Wasserman Z.R., Vaddi K., Christ D.D., Trzaskos J.M., Newton R.C., and Decicco C.P. Bioorg. Med. Chem. Lett. 18 (2008) 241
7. Ott G.R., Asakawa N., Lu Z., Liu R.-Q., Covington M.B., Vaddi K., Qian M., Newton R.C., Traskos J.M., Christ D.D., Decicco C.P., and Duan J.J.-W. Bioorg. Med. Chem. Lett. 18 (2008) 694
8. Chen X.-T., Ghavimi B., Corbett R.L., Xue C.-B., Liu R.-Q., Covington M.B., Qian M., Vaddi K.G., Christ D.D., Hartman K.D., Ribadeneira M.D., Trzaskos J.M., Newton R.C., Decicco C.P., and Duan J.J.-W. Bioorg. Med. Chem. Lett. 17 (2007) 1865
9. Wasserman Z.R., Duan J.J.-W., Voss M.E., Xue C.-B., Cherney R.J., Nelson D.J., Hardman K.D., and Decicco C.P. Chem. Biol. 10 (2003) 215
10. 50 = 263 nM).
11. For examples of the preparation of cyclic β-amino acids using a Curtius rearrangement, see:. Bolm C., Schiffers I., Atodiresei I., and Hackenberger C.P.R. Tetrahedron: Asymmetry 14 (2003) 3455
12. 1H NMR and low resolution mass spectrometry data.
13. The numbering system of the oxaspiro[4.4]nonane system is reflected in the structure.
14. The GOESY is a double-PFG-spin-echo, transient nOe experiment using shape selective pulses and pulse field gradients in which the results appear similar to a steady-state nOe difference experiment. Since excitation is done with shaped pulses, a much narrower region of the spectrum is affected so it is possible to see weaker nOes than with a steady-state nOe difference experiment, see. Stott K., Keeler J., Van Q.N., and Shaka A.J. J. Magn. Reson. 125 (1997) 302
15. The coordinates for 21 have been placed in the Cambridge Crystallographic Data Centre, deposition number: CCDC 670062.
16. Details of the pTACE (porcine TACE), MMPs, human whole blood assay (WBA) as well as LPS-mouse efficacy model are reported in previous publication, see:. Xue C.-B., Voss M.E., Nelson D.J., Duan J.J.-W., Cherney R.J., Jacobson I.C., He X., Roderick J., Chen L., Corbett R.L., Wang L., Meyer D.T., Kennedy K., DeGrado W.F., Hardman K.D., Teleha C.A., Jaffee B.D., Liu R.-Q., Copeland R.A., Covington M.B., Christ D.D., Trzaskos J.M., Newton R.C., Magolda R.L., Wexler R.R., and Decicco C.P. J. Med. Chem 44 (2001) 2636
17. Schlondorff J., Becherer J.D., and Blobel C.P. Biochem. J. 347 (2000) 131
18. Solomon K.A., Covington M.B., Decicco C.P., and Newton R.C. J. Immunol. 159 (1997) 4524
19. Wu J.-T., Zeng H., Qian M., Brogdon B.L., and Unger S.E. Anal. Chem. 72 (2000) 61
20. For related analogs in the α,β-cyclic-β-benzamido hydroxamic acid series, replacement of the 4-[(2-methylquinolin-4-yl)methoxy]benzamide P1' substituent with 4-[(2,6-dimethylpyridin-4-yl)methoxy]benzamide resulted in maintenance of pTACE activity but loss in both WBA activity and selectivity against MMPs-2 and -13. Ott, G. R.; Asakawa, N, unpublished results.